Lilly delivers one-two punch with 2nd tranche of positive data on weekly insulin candidate

Shortly after a positive data drop for Eli Lilly’s efsitora alfa, the Indianapolis-based company is again padding the case for its weekly insulin prospect.

Tuesday, Lilly revealed that efsitora met its primary endpoints for reducing the A1C measure of blood sugar across two more trials in the company's five-study QWINT phase 3 development program.